FDA OKs first gene therapy for inherited vision loss
Spark Therapeutics’ Luxturna has become the first gene therapy ever to be approved by the US Food and Drug Administration for an inherited condition.
Read More
Tag: biallelic RPE65 mutation
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
